Introduction {#Sec1}
============

For patients with type 2 diabetes mellitus (T2DM), increasing the frequency of blood glucose monitoring is beneficial for maintaining physiological blood glucose levels \[[@CR1], [@CR2]\]. Self-monitoring of blood glucose (SMBG) and hemoglobin A1c (HBA1c) are the most commonly used methods to assess short-term and long-term blood glucose control, respectively \[[@CR3]--[@CR5]\]. However, these measurements are inadequate for real-time blood glucose monitoring. A continuous glucose monitoring system (CGMS) conveniently and accurately records real-time glycemic values and trends over multiple days by providing a large number of blood glucose recordings \[[@CR2], [@CR5]--[@CR7]\]. A CGMS provides a detailed depiction of glycemic variability (GV) and efficiently analyzes rates of change in glucose levels \[[@CR7], [@CR8]\]. Wide fluctuations in blood glucose levels may lead to excessive glycosylation and oxidative stress and are associated with reduced endothelial function in patients with T2DM; these are key factors in the development of diabetic complications \[[@CR9], [@CR10]\]. Patients with glycemic lability often have long-standing diabetes with both beta-cell function and counter-regulatory hormone failure \[[@CR11]\]. GV has recently been evaluated as a potential target for diabetic complication interventions, and the GV record provided by a CGMS may improve glycemic control \[[@CR12]--[@CR14]\].

Metformin, an oral antidiabetic drug, is the first-line treatment for T2DM. In patients with T2DM and poorly controlled blood glucose receiving metformin alone, glucagon-like peptide-1 (GLP-1) receptor agonists and basal insulin are used as optional antidiabetic drugs \[[@CR15]--[@CR17]\]. Studies involving patients with T2DM and poor glycemic control receiving metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea found that the addition of exenatide minimized GV to a greater extent than the addition of insulin glargine, based on SMBG results \[[@CR18], [@CR19]\].

A previous study and meta-analysis found that liraglutide (1.8 and 1.2 mg), a long-term GLP-1 receptor agonist, provided greater reductions in HbA1c and fasting plasma glucose (FBG) than exenatide (10 μg b.i.d.), a short-term GLP-1 receptor agonist. Compared with insulin glargine, adding liraglutide or other long-term GLP-1 receptor agonists to metformin alone or with a sulfonylurea decreased body weight and led to significantly improved or at least noninferior glycemic control \[[@CR20]--[@CR22]\]. In contrast to Western countries, exenatide is a commonly and widely used short-term GLP-1 receptor agonist in China \[[@CR23], [@CR24]\]. It is unclear from the use of a CGMS, which is a reliable technology for monitoring glycemic control, whether exenatide or basal insulin has a better effect on GV for patients with T2DM and inadequate glycemic control who receive metformin. In the work described in the present paper, we used a CGMS to compare the effects of exenatide treatment with those of insulin glargine treatment on the GVs of overweight and obese T2DM patients with poor glycemic control using metformin.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Thirty-nine T2DM patients with poor glycemic control after receiving metformin monotherapy were recruited from Drum Tower Hospital (affiliated with Nanjing University Medical School, China) and randomized to receive exenatide or insulin glargine treatment for 16 weeks. Random numbers were provided by third-party statisticians and block randomization was used. Inclusion criteria were as follows: (1) a stable metformin dose ≥ 1.5 g/day over at least 8 weeks; (2) body mass index (BMI) ≥ 24 kg/m^2^; (3) HbA1c level between 7.0% and 10.0%; and (4) age between 18 and 70 years. Exclusion criteria were as follows: (1) renal dysfunction, defined as a serum creatinine level ≥ 1.5 mg/dL; (2) diseases causing acute or chronic hypoxia; (3) liver dysfunction, defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 3 times higher than the upper limit of normal; (4) history of cardiovascular disease (CVD) during the preceding year; (5) proliferative retinopathy; (6) positive pregnancy test result, breast-feeding, or refusal to use appropriate contraceptive methods; (7) systemic corticosteroid therapy during the preceding 2 months; (8) type 1 diabetes; and (9) use of other experimental drugs over the preceding 1 month. All patients included in the study provided written informed consent. The study protocol was approved by the Research Ethics Board of Drum Tower Hospital, which is affiliated with Nanjing University Medical School (Protocol: AF/SQ-2014-072-01). The present study was monitored by the Drug Clinical Trial Agency Office of Drum Tower Hospital, which is affiliated with Nanjing University Medical School. Adverse events (AEs) were collected and recorded in case report form, and serious adverse events (SAEs) were reported in written form to the Institutional Review Board of the Drug Clinical Trial Agency Office and the Research Ethics Board of Drum Tower Hospital.

Endpoint {#Sec4}
--------

The primary endpoint of this study was the change in GV during a 16-week follow-up period. Secondary endpoints included changes in the following factors at 16 weeks: blood glucose, HbA1c, weight, BMI, waist circumference, insulin function, liver function, and lipid profile.

Protocol {#Sec5}
--------

This prospective, randomized, and parallel-design trial lasted 16 weeks. For the exenatide-treated patients, the initial dosage was 5 µg twice daily for 4 weeks, followed by a maintenance dose of 10 µg twice daily throughout the trial. For patients receiving insulin glargine, the initial dose was 8 IU once daily, followed by a titrated dosage of ≥ 2 IU every 3 days based on FBG levels during the first 4 weeks until the peripheral blood glucose levels reached 6.1 mmol/L; the insulin glargine dose was not adjusted over the final 12 weeks. GV was measured at baseline and during the last week. This study was registered with Clinical trials.gov (ID: NCT02325960).

Measurements {#Sec6}
------------

### Glycemic Variability {#Sec7}

GV was assessed at baseline and at the end of the study using a CGMS (Glod, Medtronic) for up to 72 h. The CGMS sensor was inserted into subcutaneous abdominal fat tissue, and the average electrical signal was recorded every 5 min, yielding 288 glucose level measurements per day and 864 data points for 3 consecutive days. According to the CGMS results, the following key parameters were calculated: (1) mean blood glucose (MBG) level, which was estimated as the average value and standard deviation (SD) of the 288 data points recorded during the 24 h of continuous glucose monitoring; (2) mean amplitude of glycemic excursion (MAGE), determined by calculating the arithmetic mean of the difference between consecutive peaks and nadirs if the difference was \> 1 SD of mean glucose; (3) mean absolute value of daily differences, calculated as the mean absolute deviation of matched values measured during two consecutive 24-h periods of continuous glucose monitoring \[[@CR25]\]; (4) the difference between the highest and lowest levels of blood glucose, calculated as the difference between the highest and lowest blood glucose values during 24 h of continuous glucose monitoring; (5) TBG \> 7.8 mmol/L and TBG \> 11.1 mmol/L, calculated as the percentage of the time that the blood glucose value (TBG) was \> 7.8 and \> 11.1 mmol/L, respectively, during 24 h; and (6) TBG \< 3.9 mmol/L, calculated as the percentage of the time that the blood glucose value was \< 3.9 mmol/L during 24 h \[[@CR26]\].

### Standard Meal Tolerance Test {#Sec8}

All patients enrolled in our study underwent a standard meal tolerance test at baseline and after 16 weeks of intervention. Plasma glucose and insulin levels were measured 0, 30, 60, and 120 min after meal ingestion. The 1/homeostasis model assessment of insulin resistance (1/HOMA-IR) index and the Matsuda insulin sensitivity index (ISI~M~) were used to measure insulin sensitivity. The basal homeostasis model assessment of insulin secretion (HOMA-β), early-phase total insulin area under the curve divided by the total glucose area under the curve during the first 30 min of the standard meal tolerance test (InsAUC30/GluAUC30), and the total-phase total insulin area under the curve divided by the total glucose area under the curve during the 120 min of the oral glucose tolerance test (InsAUC120/GluAUC120) were used to calculate insulin release. The disposition index was used to express β-cell function \[[@CR27]--[@CR29]\]. Values were calculated using the following formulae: 1/HOMA-IR = 1/(Ins~0~ × Glu~0~/22.5); ISI~M~ = 10,000/(Glu~0~ × Ins~0~ × average glucose 75-g oral glucose tolerance test \[OGTT\] × average insulin OGTT)^1/2^; HOMA-*β* = (20 × Ins~0~)/(Glu~0~ − 3.5); InsAUC30/luAUC30 = (Ins~0~ + Ins~30~)/(Glu~0~ + Glu~30~); InsAUC120/GluAUC120 = (Ins~0~ + 4 × Ins~30~ + 3 × Ins~120~)/(Glu~0~ + 4 × Glu~30~ + 3 × Glu~120~); DI30 = (InsAUC30/GluAUC30) × ISI~M~; and DI120 = (InsAUC120/GluAUC120) × ISI~M~ \[[@CR30]\].

### Biochemical Analyses {#Sec9}

Fasting serum HBA1c, ALT, AST, total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglyceride (TG), uric acid, and creatinine levels were measured at baseline and after 16 weeks of intervention.

Statistical Analysis {#Sec10}
--------------------

Statistical analyses were performed using the SPSS version 18.0 software (SPSS Inc., Chicago, IL, USA) with a significance level of *α* = 0.05. A previous study demonstrated that insulin glargine treatment results in a MAGE change from baseline at week 36 of − 0.3 ± 1.3 \[[@CR31]\], while exenatide used twice daily results in an approximate MAGE change from baseline at week 16 of − 2.91 ± 3.15 \[[@CR32]\]. Using SMBG data \[[@CR33]\] from a head-to-head study between exenatide and glargine, we can conservatively estimate that the MAGE change from baseline in the exenatide group is approximate 2.55 ± 3.15, so the sample size per group needed to provide 80% power was calculated. Assuming a 10% subject drop-out rate, a total of 44 patients (22 per group) was targeted for randomization. Data are presented as the mean ± standard error (SE). The paired Student's *t* test was used to analyze the pre- and post-intervention differences within each group. Analysis of covariance (ANCOVA) was used to test for differences between the intervention groups after adjusting for baseline. Pearson's correlation analysis was conducted to determine the association between the variables and GV and HBA1c. *P* values of \< 0.05 were considered significant.

Compliance with Ethics Guidelines {#Sec11}
---------------------------------

All procedures performed in studies involving human participants were done in accordance with the ethical standards of the institutional and/or national research committee, as well as with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all participants included in the study.

Results {#Sec12}
=======

Baseline Characteristics {#Sec13}
------------------------

Out of the 52 patients treated with metformin monotherapy, 3 were not willing to participate in the trial and 4 did not meet the inclusion criteria. In total, 45 patients were randomized into the two treatment groups: 22 received exenatide therapy and 23 received insulin glargine therapy. Three patients in each group refused to undergo continuous glucose monitoring again after 16 weeks of intervention. Therefore, 39 patients completed the study (Fig. [1](#Fig1){ref-type="fig"}). The baseline characteristics of the patients in the two treatment groups, including age and diabetes duration, were well matched (Table [1](#Tab1){ref-type="table"}).Fig. 1Flow chart of study participants. Of the 52 participants recruited for the present study, 3 were unwilling to participate and 4 did not meet the inclusion criteria Table 1Subject characteristics at baseline and after treatmentExenatideInsulin glargineChange in valueEstimated difference in value between groups\
Mean (95% CI)*P*Before treatment\
Mean ± SEAfter treatment\
Mean ± SE*P*Before treatment\
Mean ± SEAfter treatment\
Mean ± SE*P*Exenatide\
Mean (95% CI)Insulin glargine\
Mean (95% CI)Number (*n*)19----20----------**--**Sex (male/female)12/7----10/10----------**--**Age46.74 ± 2.31----49.45 ± 2.17----------**--**Diabetic duration6.37 ± 0.99----4.35 ± 0.68----------**--**Weight (kg)80.36 ± 2.3576.85 ± 2.36\< 0.00174.75 ± 1.9575.20 ± 1.980.263− 3.51 (− 5.09 to − 1.93)0.45 (− 0.37 to 1.27)− 3.96 (− 5.65 to − 2.27)\< 0.001BMI (kg/m^2^)28.03 ± 0.5026.81 ± 0.51\< 0.00127.08 ± 0.5227.24 ± 0.550.258− 1.22 (− 1.78 to − 0.65)0.17 (− 0.13 to 0.47)− 1.38 (− 1.99 to − 0.77)\< 0.001Waist circumference (cm)96.74 ± 1.5093.71 ± 1.590.01293.70 ± 1.5293.30 ± 1.480.366− 3.03 (− 5.30 to − 0.75)− 0.40 (− 1.30 to 0.50)− 2.62 (− 5.03 to − 0.22)0.061ALT (U/L)31.79 ± 4.3331.56 ± 3.960.94936.46 ± 4.8228.83 ± 3.810.027− 0.23 (− 7.75 to 7.28)− 7.63 (− 14.27 to − 0.99)7.39 (− 2.27 to 17.05)0.183AST (U/L)22.28 ± 2.1321.97 ± 2.180.85524.78 ± 2.1522.39 ± 1.920.103− 0.32 (− 3.92 to 3.29)− 2.39 (− 5.31 to 0.53)2.07 (− 2.37 to 6.51)0.522TG (mmol/L)1.75 ± 0.171.61 ± 0.230.2861.70 ± 0.171.49 ± 0.190.295− 0.15 (− 0.42 to 0.13)− 0.21 (− 0.63 to 0.20)0.07 (− 0.42 to 0.55)0.744TC (mmol/L)4.55 ± 0.314.04 ± 0.280.0194.45 ± 0.234.30 ± 0.150.557− 0.51 (− 0.93 to − 0.10)− 0.14 (− 0.64 to 0.35)− 0.37 (− 1.00 to 0.25)0.183HDL (mmol/L)1.04 ± 0.051.00 ± 0.060.3241.03 ± 0.051.11 ± 0.070.147− 0.04 (− 0.11 to 0.04)0.09 (− 0.03 to 0.21)− 0.12 (− 0.26 to 0.01)0.083LDL (mmol/L)2.42 ± 0.212.07 ± 0.200.0102.36 ± 0.172.28 ± 0.110.617− 0.35 (− 0.60 to − 0.10)− 0.09 (− 0.44 to 0.27)− 0.26 (− 0.69 to 0.16)0.153*P* values of \< 0.05 were considered to indicate significant differences between the groups*BMI* body mass index, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *TG* triglyceride, *TC* total cholesterol, *LDL* low-density lipoprotein cholesterol, *HDL* high-density lipoprotein cholesterol

Biomedical Parameters {#Sec14}
---------------------

After intervention, body weight (Δ = − 3.51 kg, *P * \< 0.001), BMI (Δ = − 1.22 kg/m^2^, *P * \< 0.001), and waist circumference (Δ = − 3.03 cm, *P  *= 0.012) significantly decreased in the exenatide treatment group but did not change in the insulin glargine group. Larger reductions in body weight (− 3.96 kg; 95% CI −5.65 to − 2.27 kg; *P * \< 0.001) and BMI (− 1.38 kg/m^2^; 95% CI − 1.99 to − 0.77 kg/m^2^; *P  *\< 0.001) occurred in the exenatide group compared with the insulin glargine group. Although TC (*P * = 0.019) and LDL (*P  *= 0.010) levels were significantly reduced after exenatide intervention, and ALT (*P  *= 0.027) levels were significantly decreased after the insulin glargine treatment, there were no significant differences between the two groups (Table [1](#Tab1){ref-type="table"}).

Glycemic Control and Insulin Function {#Sec15}
-------------------------------------

After 16 weeks of intervention, HbA1c was significantly reduced by both exenatide treatment and by insulin glargine treatment (exenatide 8.01 ± 0.21 vs 6.83 ± 0.25%, Δ = − 1.18%, *P * \< 0.001; insulin glargine 8.35 ± 0.24 vs 7.14 ± 0.16%, Δ = − 1.21%, *P  *\< 0.001; Table [2](#Tab2){ref-type="table"}). Both exenatide and insulin glargine significantly reduced FBG (*P  *= 0.002, *P * = 0.007, respectively); the blood glucose level measured at 30 min (*P * = 0.009) using a standard meal tolerance test was found to be significantly decreased with insulin glargine treatment (Table [2](#Tab2){ref-type="table"}). The exenatide treatment group exhibited larger decreases in FBG (− 0.17 mmol/L; 95% CI − 1.64 to 1.30 mmol/L) and HbA1c (− 0.16%; 95% CI − 0.67% to 0.35%) than the insulin glargine group, although there were no statistical differences between the two groups (Table [2](#Tab2){ref-type="table"}). Following both treatments, increases in 1/HOMA-IR (exenatide: from 0.35 ± 0.05 to 0.54 ± 0.08 μIU/mL, mmol/L, *P *= 0.035; insulin glargine: from 0.28 ± 0.03 to 0.47 ± 0.06 μIU/mL, mmol/L, *P * = 0.017), ISI~M~ (exenatide: from 4.43 ± 0.71 to 7.13 ± 1.06 μIU/mL, mmol/L, *P  *= 0.035), disposition index 30 (exenatide: from 41.94 ± 5.30 to 68.50 ± 11.06 mmol/L, mmol/L, *P * = 0.008; insulin glargine: from 36.40 ± 4.40 to 60.39 ± 6.24 mmol/L, mmol/L, *P * = 0.001), and disposition index 120 (exenatide: from 61.31 ± 9.64 to 97.12 ± 17.30 mmol/L, mmol/L, *P  *= 0.020; insulin glargine: from 52.71 ± 6.87 to 88.33 ± 10.21 mmol/L, mmol/L, *P  *= 0.006) were observed (Table [2](#Tab2){ref-type="table"}); however, there were no statistical differences between the two groups.Table 2Glucose control, insulin sensitivity, and β-cell function at baseline and after treatmentExenatideInsulin glargineChange in valueEstimated difference in value between groups\
Mean (95% CI)*P*Before treatment\
Mean ± SEAfter treatment\
Mean ± SE*P*Before treatment\
Mean ± SEAfter treatment\
Mean ± SE*P*Exenatide\
Mean (95% CI)Insulin glargine\
Mean (95% CI)FBG (mmol/L)8.65 ± 0.536.88 ± 0.400.0028.83 ± 0.487.23 ± 0.390.007− 1.77 (− 2.83 to − 0.72)− 1.60 (− 2.70 to − 0.50)− 0.17 (− 1.64 to 1.30)0.58030 min glucose (mmol/L)11.03 ± 0.749.06 ± 0.870.06111.90 ± 0.6810.08 ± 0.590.009− 1.97 (− 4.05 to 0.10)− 1.82 (− 3.13 to − 0.52)− 0.15 (− 2.48 to 2.19)0.49760 min glucose (mmol/L)14.27 ± 0.9911.82 ± 1.030.08014.70 ± 0.6712.18 ± 0.660.091− 2.45 (− 5.23 to 0.33)− 2.52 (− 3.92 to − 1.12)0.08 (− 2.82 to 2.97)0.844120 min glucose (mmol/L)13.31 ± 0.8811.71 ± 0.750.10613.99 ± 0.9012.77 ± 0.860.204− 1.59 (− 3.56 to 0.38)− 1.22 (− 3.17 to 0.74)− 0.37 (− 3.04 to 2.29)0.457Fasting insulin (uIU/mL)10.92 ± 1.8510.03 ± 1.750.70110.48 ± 1.029.62 ± 1.880.671− 0.89 (− 5.71 to 3.93)− 0.86 (− 5.07 to 3.35)− 0.03 (− 6.22 to 6.15)0.90330 min insulin (uIU/mL)19.69 ± 3.0317.57 ± 3.960.52318.47 ± 2.1222.48 ± 4.830.388− 2.12 (− 8.99 to 4.74)4.01 (− 5.57 to 13.59)− 6.13 (− 17.37 to 5.10)0.29860 min insulin (uIU/mL)30.26 ± 5.4833.86 ± 8.820.64629.92 ± 3.5333.99 ± 6.260.5253.60 (− 12.64 to 19.84)4.06 (− 9.19 to 17.32)− 0.46 (− 20.78 to 19.85)0.970120 min insulin (uIU/mL)35.65 ± 5.6139.33 ± 8.870.54938.38 ± 6.0544.93 ± 8.610.4363.67 (− 9.00 to 16.35)6.54 (− 10.81 to 23.90)− 2.87 (− 23.36 to 17.62)0.7561/HOMA-IR (μIU/mL, mmol/L)0.35 ± 0.050.54 ± 0.080.0350.28 ± 0.030.47 ± 0.060.0170.19 (0.02 to 0.37)0.19 (0.04 to 0.33)0.00 (− 0.22 to 0.22)0.718ISI~M~ (μIU/mL, mmol/L)4.43 ± 0.717.13 ± 1.060.0353.81 ± 0.545.29 ± 0.700.0592.70 (0.22 to 5.19)1.48 (− 0.07 to 3.03)1.22 (− 1.62 to 4.06)0.218HOMA-B (IU/mol)55.55 ± 11.55120.79 ± 48.440.15354.17 ± 10.9084.09 ± 30.500.36165.24 (− 26.68 to 157.17)29.91 (− 37.74 to 97.57)35.33 (− 76.88 to 147.54)0.536InsAUC30/GluAUC30 (IU/mol)12.09 ± 1.9015.29 ± 3.320.18111.20 ± 1.6414.77 ± 3.200.2373.20 (− 1.65 to 8.05)3.58 (− 2.613 to 9.76)− 0.37 (− 7.86 to 7.11)0.898InsAUC120/GluAUC120 (IU/mol)17.39 ± 3.1722.03 ± 5.780.15816.43 ± 2.7321.94 ± 4.630.2274.64 (− 2.02 to 11.29)5.51 (− 3.88 to 14.90)− 0.87 (− 11.64 to 9.89)0.836DI 30 (mmol/L, mmol/L)41.94 ± 5.3068.50 ± 11.060.00836.40 ± 4.4060.39 ± 6.240.00126.57 (8.20 to 44.93)23.99 (12.71 to 35.27)2.57 (− 18.36 to 23.51)0.872DI 120 (mmol/L, mmol/L)61.31 ± 9.6497.12 ± 17.300.02052.71 ± 6.8788.33 ± 10.210.00635.81 (6.65 to 64.97)35.62 (12.24 to 59.00)0.19 (− 35.79 to 36.17)0.949HbA1c (%)8.01 ± 0.216.83 ± 0.25\< 0.0018.35 ± 0.247.14 ± 0.16\< 0.001− 1.21 (− 1.57 to − 0.85)− 1.05 (− 1.41 to − 0.69)− 0.16 (− 0.67 to 0.35)0.537InsAUC30/GluAUC30 was calculated as the total insulin area under the curve divided by the total glucose area under the curve during the first 30 min of the 75-g oral glucose tolerance test (OGTT); InsAUC120/GluAUC120 was calculated as the total insulin area under the curve divided by the total glucose area under the curve during the 120 min of the OGTT*P* values of \< 0.05 were considered to indicate significant differences between the groups*FBG* fasting blood glucose, *1/HOMA-IR* 1/homeostasis model assessment of insulin resistance, *ISIM* Matsuda insulin sensitivity index, *HOMA-β* basal homeostasis model assessment of insulin secretion, *DI30* disposition index 30, *DI120* disposition index 120, *HbA1c* hemoglobin A1c

Continuous Glucose Monitoring {#Sec16}
-----------------------------

Overall, blood glucose fluctuations significantly improved after the exenatide and insulin glargine treatments (Fig. [2](#Fig2){ref-type="fig"}). There were similarly significant reductions in the MBG (exenatide Δ = − 1.25 ± 0.29 mmol/L, *P * \< 0.001; insulin glargine Δ = − 1.83 ± 0.66 mmol/L, *P  *= 0.007), continuous overlapping net glycemic action (CONGA) (exenatide Δ = − 1.13 ± 0.30 mmol/L, *P  *\< 0.001; insulin glargine Δ = − 2.09 ± 0.70 mmol/L, *P * = 0.015), and MAGE (exenatide Δ = − 1.20 ± 0.54 mmol/L, *P  *= 0.001; insulin glargine Δ = − 1.47 ± 0.52 mmol/L, *P  *= 0.001) values after the exenatide and insulin glargine interventions. There appeared to be smaller decreases in MBG (0.36 mmol/L; 95% CI − 1.00 to 1.72 mmol/L), CONGA (0.45 mmol/L; 95% CI − 0.94 to 1.84 mmol/L), and MAGE (0.20 mmol/L; 95% CI − 1.00 to 1.41 mmol/L) in the exenatide group when compared to the insulin glargine group, although there were no statistically significant differences. After exenatide intervention, there were significant reductions in the standard deviation of the mean glucose (Δ = 0.70 ± 0.24 mmol/L, *P  *= 0.001) and largest amplitude of glycemic excursions (Δ = − 2.32 ± 1.06 mmol/L, *P  *= 0.004), while no changes were observed after the insulin glargine intervention (Table [3](#Tab3){ref-type="table"}).Fig. 2Mean interstitial glucose values at baseline and after treatment with exenatide (**a**) and insulin glargine (**b**) Table 3Glycemic variability at baseline and after treatmentExenatideInsulin glargineChange in valueEstimated difference in value between groups\
Mean (95% CI)*P*Before treatment\
Mean ± SEAfter treatment\
Mean ± SE*P*Before treatment\
Mean ± SEAfter treatment\
Mean ± SE*P*Exenatide\
Mean (95% CI)Insulin glargine\
Mean (95% CI)MBG (mmol/L)9.77 ± 0.408.32 ± 0.44\< 0.00110.85 ± 0.549.04 ± 0.540.007− 1.45 (− 2.06 to − 0.85)− 1.82 (− 3.01 to − 0.57)0.36 (− 1.00 to 1.72)0.824SDBG (mmol/L)1.87 ± 0.151.19 ± 0.130.0012.02 ± 0.141.71 ± 0.160.187− 0.68 (− 1.06 to − 0.31)− 0.31 (− 0.79 to 0.17)− 0.37 (− 0.96 to 0.21)0.022MODD (mmol/L)1.75 ± 0.211.52 ± 0.170.2152.01 ± 0.181.82 ± 0.130.248− 0.24 (− 0.63 to 0.16)− 0.19 (− 0.53 to 0.15)− 0.05 (− 0.53 to 0.44)0.294MAGE (mmol/L)4.51 ± 0.322.94 ± 0.330.0015.62 ± 0.463.84 ± 0.390.001− 1.57 (− 2.42 to − 0.73)− 1.78 (− 2.70 to − 0.86)0.20 (− 1.00 to 1.41)0.322LAGE (mmol/L)7.82 ± 0.595.18 ± 0.530.0048.60 ± 0.636.97 ± 0.870.166− 2.64 (− 4.29 to − 0.99)− 1.63 (− 4.01 to 0.75)− 1.00 (− 3.77 to 1.77)0.083CONGA (mmol/L)8.82 ± 0.397.53 ± 0.40\< 0.0019.55 ± 0.497.80 ± 0.470.015− 1.30 (− 1.91 to − 0.68)− 1.75 (− 3.12 to − 0.38)0.45 (− 0.94 to 1.84)0.973*P* values of \< 0.05 were considered to indicate statistically significant differences between the groups*MBG* mean blood glucose level, *SDBG* standard deviation of the mean glucose value, *MODD* absolute mean of daily differences, *MAGE* mean amplitude of glycemic excursions, *LAGE* largest amplitude of glycemic excursions, *CONGA* continuous overlapping net glycemic action

Both interventions significantly decreased the percentage of the time that TBG \> 10.0 mmol/L \[exenatide Δ = − 14.79 ± 4.97%, *P * = 0.008; insulin glargine Δ = − 25.11 ± 10.16%, *P * = 0.024 (Fig. [3](#Fig3){ref-type="fig"}b)\] and the highest blood glucose level \[exenatide Δ = − 2.70 ± 0.72 mmol/L, *P  *= 0.001; insulin glargine Δ = − 2.49 ± 1.16 mmol/L, *P * = 0.045 (Fig. [3](#Fig3){ref-type="fig"}e)\]. The percentage of the time that TBG was \> 7.8 mmol/L was significantly decreased in the insulin glargine treatment group (*P  *= 0.030) but not in the exenatide group (Fig. [3](#Fig3){ref-type="fig"}a). However, there were no statistically significant differences between the two groups.Fig. 3Effects of exenatide treatment and glargine treatment on the percentage of the time that the blood glucose value (TBG) was \> 7.8 mmol/L (**a**), \> 10.0 mmol/L (**b**), or \> 11.1 mmol/L (**c**) as well as the lowest (**d**) and the highest (**e**) blood glucose (*BG*) values. \**P * \< 0.05, 16 weeks vs baseline

Correlative Analysis {#Sec17}
--------------------

For all subjects, there were significant positive correlations between ΔHbA1c and the reductions in MBG, CONGA, and Max BG (0 \< *r * \< 1; *P * \< 0.05; Table [4](#Tab4){ref-type="table"}).Table 4Correlations between glycemic variability and glycated hemoglobin∆HBA1c*rP*∆MBG (mmol/L)0.4980.001∆CONGA (mmol/L)0.5120.002∆Max BG (mmol/L)0.4390.006*P * \< 0.05 was considered to indicate statistical significance*MBG* mean blood glucose level, *CONGA* continuous overlapping net glycemic action, *HbA1c* hemoglobin A1c

Discussion {#Sec18}
==========

This study compared the effects of treatment with the short-term GLP-1 receptor agonist exenatide and insulin glargine treatment on GV in overweight and obese patients with T2DM and poor glycemic control who were receiving metformin monotherapy. Importantly, our results using a CGMS revealed that similar improvements in GV, HBA1c, and β-cell function were achieved with exenatide treatment and insulin glargine treatment, although greater body weight and BMI reductions were achieved with the exenatide treatment during the 16-week intervention. After treatment, waist circumference was significantly decreased in the exenatide group, but there was no statistically significant difference between the two groups.

Recent studies have suggested that glycemic fluctuation is a useful indicator of the effectiveness of blood glucose control and the prevention of diabetes complications \[[@CR1], [@CR2], [@CR10]\]. Less frequent monitoring of blood glucose levels using SMBG may lead to inaccurate GV assessment and could falsely suggest a lack of or a decrease in glycemic fluctuation \[[@CR3], [@CR5], [@CR6]\]. A CGMS automatically records blood glucose levels every 5 min, achieving up to 288 measurements per day, which provide a better measure of the extent of glycemic fluctuation and overall trends \[[@CR7], [@CR8]\]. Therefore, we used a CGMS in this study to monitor blood glucose.

Glycemic fluctuation following the use of a GLP-1 receptor agonist was compared with the GV observed after the introduction of basal insulin. Results showed that although the exenatide and glargine treatments were both associated with similar significant improvements in HbA1c from baseline, exenatide treatment resulted in greater improvements in GV than insulin glargine treatment for previously uncontrolled glucose levels when combined with metformin and sulfonylurea therapy. Improvements in GV were also observed in patients with suboptimally controlled diabetes using metformin or a sulfonylurea \[[@CR18], [@CR19]\]. However, the average daily risk range as well as the low and high blood glucose indices, indicative of the fluctuation in blood glucose levels, were based on SMBG and not on the more accurate CGMS \[[@CR18], [@CR19]\]. We found that FBG and HbA1c were significantly reduced after exenatide and insulin glargine intervention. Compared with baseline levels, glycemic fluctuation results calculated by the CGMS indicated that both exenatide treatment and insulin glargine treatment significantly decreased MBG, CONGA, MAGE, and the highest blood glucose value, as well as the percentage of time that the blood glucose was \> 10.0 mmol/L through the day. Following the standard meal tolerance test, insulin glargine significantly decreased blood glucose levels at 30 min; glucose levels at 60 and 120 min showed a downward trend after exenatide intervention and insulin glargine intervention. The decrease in MAGE with insulin glargine treatment might due to improved β-cell function and insulin resistance associated with improved glycemic control.

Other long-term GLP-1 receptor agonists that only require once-daily or once a week injection have become widely used or are beginning to find wider use in China. The long-term GLP-1 receptor agonists liraglutide and semaglutide have shown beneficial effects on CVD and mortality-related CVD in T2DM patients, although there would appear to be no difference in the effects of once-weekly exenatide, the other long-term GLP-1 receptor agonist, or lixisenatide, a short-term GLP-1 receptor agonist \[[@CR34]--[@CR36]\]. HbA1c and FBG showed greater reductions with liraglutide treatment rather than exenatide treatment \[[@CR23], [@CR24]\], and significantly greater improvements in HbA1c were seen with liraglutide and semaglutide than with insulin glargine \[[@CR20]--[@CR22]\]. Whether the beneficial effects of liraglutide and semaglutide for CVD were the result of greater decreases in GV requires further study.

Regarding insulin resistance and β-cell function, the 1/HOMA-IR, disposition index 30, and disposition index 120 improved with either exenatide treatment or insulin glargine treatment. Only the ISI~M~ improved to a greater extent with exenatide treatment than with insulin glargine treatment. These results indicate that β-cell function and insulin resistance improved following a 16-week course of exenatide or insulin glargine treatment.

Overweight and obese patients in the cooperative meta-analysis group of the China Obesity Task Force were enrolled in our study \[[@CR25]\]. The results showed that exenatide treatment resulted in weight loss while insulin glargine treatment did not. Standardized weight is an important part of integrated T2DM management because weight loss is associated with improvements in β-cell function and insulin action, it makes long-term glycemic control management easier, and it may favorably affect other comorbid diseases such as dyslipidemia, hypertension, and hyperuricemia \[[@CR15]\]. An increasing waist circumference contributes to central obesity and is an independent risk factor for T2DM, dyslipidemia, hypertension, and CVD \[[@CR26], [@CR37]\]. In the present study, waist circumference only decreased in the exenatide-treated group.

An important finding from our study was a positive association between GV and HbA1c level, which may indicate that exenatide and insulin glargine facilitate glycemic control and reduce GV, thus aiding diabetes management.

The main AEs reported in the exenatide-treated group were gastrointestinal intolerance/appetite suppression (17 subjects), nausea (which relieved over time; 3 subjects), and abdominal distension (4 subjects). No patients in the group treated with insulin glargine suffered gastrointestinal intolerance, hypoglycemia, or other AEs. No hypoglycemia events occurred in these patients, which may be because prandial insulin and drugs stimulating insulin secretion were not used. No participants withdrew from the study due to these AEs, and no SAEs occurred in the present study.

There are a number of limitations of our study. Only 39 patients were enrolled, and this small sample size may have had a negative impact on the statistical analysis. It might affect the comparison of waist circumference between the two intervention groups, for greater reduction of waist circumference in exenatide group might be confirmed after enlarging the sample size. The results of the present study could be further confirmed by expanding the sample size, using a blinded design, testing long-term GLP-1 receptor analogists, and potentially developing a multicenter research study. In addition, the study period was 16 weeks, which may not have been sufficient to assess additional benefits relating to the GV. Since a fixed dosage of exenatide was given in the exenatide group after 4 weeks and the dosage of the insulin glargine was only titrated during the first four weeks, rising FBG levels in some insulin-glargine-treated patients during the following 12 weeks may have affected glucose control in the insulin glargine group.

Conclusions {#Sec19}
===========

Our study showed that comparable improvements in GV, HBA1c, and β-cell function can be achieved in overweight and obese T2DM patients with inadequate glycemic control who were receiving metformin monotherapy by combining that treatment with either exenatide or insulin glargine. Compared to insulin glargine, exenatide had a superior impact on body weight and BMI. Waist circumference was significantly reduced with exenatide treatment, but there was no statistically significant difference from the insulin glargine treatment.
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